Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32‐week real‐world experience during the COVID‐19 pandemic

Dear Editor, Real‐life data concerning dupilumab effectiveness and safety in adolescents (aged ≥ 12 to <18 years) with moderate to severe atopic dermatitis (AD) are rarely reported.1 In two adolescence studies, the phase III randomized, placebo‐controlled, clinical trial (LIBERTY AD ADOL)2 and the phase IIa and subsequent phase III open‐label extension (LIBERTY AD PED‐OLE)3 dupilumab produced significant improvement in signs and symptoms at Week 16, with a good safety profile. We report our real‐life experience in using dupilumab to treat AD in adolescents. This was a 32‐week prospective real‐life study. The study was approved by the ethics committees of the participating institutions, and informed consent from patients and parents were obtained. Nine adolescents (mean age 15.7 years) with moderate to severe AD who were started on dupilumab from January to October 2020 under the Italian Medicine Agency compassionate use programme were included in this study. Data on demographics and AD clinical characteristics at baseline are reported in Table 1.